Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Define the pattern of YAP1-bound genes in pancreatic cancer spheroids.

ABSTRACT: In this study, we investigate the genes that are preferentially bound by YAP1 in pancreatic cancer spheroids.

ORGANISM(S): Homo sapiens

PROVIDER: GSE263031 | GEO | 2026/02/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

YAP1 interactome in PATU8902 pancreatic cancer spheroids.

Project description:This study aims to characterize the YAP1 interactome in human pancreatic cancer spheroids.

2024-04-05 | MSV000094472 | MassIVE

Effects of constitutive YAP1 activation on gene expression in pancreatic cancer spheroids [EV_YS6A_RNASeq]

Project description:In this study, we investigate the role of YAP1 in regulating autophagy flux in pancreatic cancer spheroids.

2026-02-15 | GSE263000 | GEO

human hTERT-RPE1 cell spheroid : Control siRNA transfected vs. YAP1 siRNA transfected

Project description:Transcriptional profiling of human hTERT-RPE1 cell spheroids comparing Control siRNA transfected hTERT-RPE1 cell spheroids with those transfected with YAP1 siRNA. Two-condition experiment, Control siRNA vs.YAP1 siRNA hTERT-RPE1 cell spheroids. Biological replicates: 1 Control siRNA, 1YAP1 siRNA transfected, independently grown and harvested. Bothreplicates per array.

2015-02-01 | E-GEOD-54146 | biostudies-arrayexpress

Effects of NF2 deletion on gene expression in pancreatic cancer spheroids [sgLUC_sgNF2_RNASeq]

Project description:In this study, we investigate the role of NF2 in regulating autophagy flux in pancreatic cancer spheroids.

2026-02-15 | GSE262999 | GEO

Loss of the Wild-type KRAS Allele Promotes Pancreatic Cancer Progression through Functional Activation of YAP1

Project description:Loss of the Wild-type KRAS Allele Promotes Pancreatic Cancer Progression through Functional Activation of YAP1

| MSV000088107 | MassIVE

human hTERT-RPE1 cell spheroid : Control siRNA transfected vs. YAP1 siRNA transfected

Project description:Transcriptional profiling of human hTERT-RPE1 cell spheroids comparing Control siRNA transfected hTERT-RPE1 cell spheroids with those transfected with YAP1 siRNA.

2015-02-01 | GSE54146 | GEO

YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma

Project description:Transcriptomic profiling classifies pancreatic ductal adenocarcinoma (PDAC) into several molecular subtypes with distinctive histological and clinical characteristics. However, little is known about the molecular mechanisms that define each subtype and how this correlates with clinical outcome. Mutant KRAS is the most prominent driver in PDAC, present in over 90% of tumors, but the dependence of tumors on oncogenic KRAS signaling varies between subtypes. In particular, squamous subtype PDACs are relatively independent of oncogenic KRAS signaling and typically display much more aggressive clinical behavior versus progenitor subtype PDACs. Here, we identified that YAP1 activation is enriched in the squamous subtype and associated with poor prognosis. Activation of YAP1 in progenitor subtype cancer cells profoundly enhanced malignant phenotypes and transformed progenitor subtype cells into squamous subtype. Conversely, depletion of YAP1 specifically suppressed tumorigenicity of squamous subtype PDAC tumors. Mechanistically, we uncovered a significant positive correlation between WNT5A expression and the YAP activation signature, and we demonstrated that WNT5A overexpression led to YAP activation and recapitulated YAP1-dependent but but Kras-independent phenotype of tumor progression and maintenance. Thus, our study identifies YAP1 oncogene as a major driver of squamous subtype PDAC and uncovers the role of WNT5A to drive PDAC malignancy via activation of the YAP pathway.

2019-10-01 | GSE135754 | GEO

Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer (part 2)

Project description:Activating mutations in KRAS are among the most frequent events in diverse human carcinomas and are particularly prominent in human pancreatic ductal adenocarcinoma (PDAC). An inducible KrasG12D-driven mouse model of PDAC has established a critical role for sustained KrasG12D expression in tumor maintenance, providing a model to determine the potential for, and underlying mechanisms of, KrasG12D–independent PDAC recurrence. Here we show that some tumors undergo spontaneous relapse and are devoid of KrasG12D expression and downstream canonical MAPK signaling and instead acquired amplification and overexpression of the transcriptional co-activator Yap1. Functional studies established the role of Yap1 and the transcriptional factor Tead2 in driving KrasG12D–independent tumor maintenance. The Yap1/Tead2 complex acts cooperatively with E2F transcription factors to activate a cell cycle and DNA replication program. Our studies, along with corroborating evidence from human PDAC models, portend a novel mechanism of escape from oncogenic Kras addiction in PDAC.

2014-12-31 | GSE53168 | GEO

Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer (part 1)

2014-12-31 | GSE53167 | GEO

Multicellular spheroids treated with the compound VLX600

Project description:Microarray based mRNA profiling was used to charactarize the response to the compound VLX600 in cells grown as spheroids. Cells used was colon cancer cells HCT116 and HCT116HIF1a knock-out. We identify the small molecule VLX600 as a drug that is preferentially active against quiescent cells in colon cancer 3-D microtissues. The anticancer activity is associated with reduced mitochondrial respiration, leading to a bioenergetic catastrophe and tumor cell death. VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation. Microarray based mRNA profiling was used to charactarize the response to the compound VLX600 in cells grown as spheroids. Cells used was colon cancer cells HCT116 and HCT116HIF1a knock-out cells.

2014-02-17 | E-GEOD-53777 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data